Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 24 | 2024 | 282 | 5.870 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2023 | 181 | 1.410 |
Why?
|
| Primary Graft Dysfunction | 3 | 2023 | 37 | 1.240 |
Why?
|
| Esophagectomy | 5 | 2021 | 92 | 1.140 |
Why?
|
| Esophageal Neoplasms | 3 | 2021 | 332 | 0.900 |
Why?
|
| Respiratory Insufficiency | 2 | 2022 | 161 | 0.810 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 115 | 0.740 |
Why?
|
| Subclavian Vein | 1 | 2020 | 15 | 0.730 |
Why?
|
| Femoral Vein | 1 | 2020 | 39 | 0.720 |
Why?
|
| Cannula | 1 | 2020 | 50 | 0.720 |
Why?
|
| Jehovah's Witnesses | 1 | 2020 | 20 | 0.720 |
Why?
|
| Jugular Veins | 1 | 2020 | 74 | 0.710 |
Why?
|
| Hospitals, High-Volume | 1 | 2020 | 36 | 0.710 |
Why?
|
| Walking | 1 | 2020 | 89 | 0.700 |
Why?
|
| Retrospective Studies | 22 | 2024 | 8960 | 0.680 |
Why?
|
| Hernia, Hiatal | 1 | 2019 | 38 | 0.660 |
Why?
|
| Catheterization | 1 | 2020 | 237 | 0.660 |
Why?
|
| Simulation Training | 1 | 2020 | 96 | 0.630 |
Why?
|
| Herniorrhaphy | 1 | 2019 | 90 | 0.630 |
Why?
|
| Pneumonectomy | 1 | 2020 | 206 | 0.600 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 256 | 0.570 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 423 | 0.550 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 405 | 0.510 |
Why?
|
| Lung | 6 | 2024 | 1253 | 0.510 |
Why?
|
| Tissue and Organ Procurement | 3 | 2023 | 343 | 0.450 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2023 | 157 | 0.440 |
Why?
|
| Humans | 37 | 2024 | 88835 | 0.420 |
Why?
|
| Laparoscopy | 1 | 2019 | 771 | 0.410 |
Why?
|
| Waiting Lists | 3 | 2023 | 182 | 0.380 |
Why?
|
| Tissue Donors | 4 | 2023 | 489 | 0.370 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1113 | 0.370 |
Why?
|
| Liver Diseases | 2 | 2022 | 242 | 0.350 |
Why?
|
| Treatment Outcome | 8 | 2023 | 8177 | 0.330 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 2344 | 0.290 |
Why?
|
| Liver Transplantation | 2 | 2023 | 1175 | 0.250 |
Why?
|
| Adult | 11 | 2024 | 26437 | 0.220 |
Why?
|
| Liver Failure | 1 | 2023 | 67 | 0.220 |
Why?
|
| Syndecan-1 | 1 | 2023 | 16 | 0.220 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2023 | 73 | 0.220 |
Why?
|
| Intraoperative Care | 1 | 2023 | 84 | 0.210 |
Why?
|
| Situs Inversus | 1 | 2022 | 15 | 0.210 |
Why?
|
| United States | 5 | 2023 | 6928 | 0.200 |
Why?
|
| Middle Aged | 8 | 2023 | 25783 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 55 | 0.200 |
Why?
|
| Thoracic Surgery | 1 | 2022 | 43 | 0.200 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2022 | 55 | 0.190 |
Why?
|
| Esophagoscopy | 1 | 2021 | 89 | 0.190 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 60 | 0.180 |
Why?
|
| Aftercare | 1 | 2021 | 87 | 0.180 |
Why?
|
| Gastropexy | 1 | 2019 | 2 | 0.180 |
Why?
|
| Travel | 1 | 2020 | 71 | 0.170 |
Why?
|
| Registries | 2 | 2024 | 770 | 0.170 |
Why?
|
| Social Class | 1 | 2020 | 135 | 0.170 |
Why?
|
| Donor Selection | 1 | 2020 | 74 | 0.170 |
Why?
|
| Thoracic Duct | 1 | 2019 | 4 | 0.170 |
Why?
|
| Chylothorax | 1 | 2019 | 9 | 0.170 |
Why?
|
| Geography | 1 | 2020 | 227 | 0.170 |
Why?
|
| Heart Arrest | 1 | 2023 | 279 | 0.170 |
Why?
|
| Propensity Score | 1 | 2020 | 146 | 0.170 |
Why?
|
| Gastroplasty | 1 | 2019 | 25 | 0.170 |
Why?
|
| Esophageal Diseases | 1 | 2019 | 27 | 0.170 |
Why?
|
| Risk Assessment | 2 | 2020 | 2285 | 0.170 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2021 | 188 | 0.170 |
Why?
|
| Aged | 6 | 2023 | 19014 | 0.160 |
Why?
|
| Transplant Recipients | 1 | 2020 | 137 | 0.160 |
Why?
|
| Fundoplication | 1 | 2019 | 78 | 0.160 |
Why?
|
| Anastomosis, Surgical | 1 | 2020 | 273 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 366 | 0.160 |
Why?
|
| Acute Disease | 1 | 2020 | 837 | 0.160 |
Why?
|
| Female | 9 | 2023 | 45893 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 253 | 0.150 |
Why?
|
| Suture Techniques | 1 | 2019 | 140 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 1095 | 0.150 |
Why?
|
| Lung Diseases | 1 | 2020 | 269 | 0.150 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 1194 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2022 | 473 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1835 | 0.140 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 178 | 0.140 |
Why?
|
| Aortic Valve | 1 | 2019 | 243 | 0.140 |
Why?
|
| Recurrence | 1 | 2020 | 1140 | 0.140 |
Why?
|
| Patient Safety | 1 | 2019 | 215 | 0.140 |
Why?
|
| Embolization, Therapeutic | 1 | 2019 | 262 | 0.140 |
Why?
|
| Biomarkers | 1 | 2023 | 1751 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2022 | 849 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1698 | 0.130 |
Why?
|
| Time Factors | 2 | 2023 | 5311 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 2853 | 0.120 |
Why?
|
| HIV Infections | 1 | 2024 | 830 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1354 | 0.120 |
Why?
|
| Male | 7 | 2023 | 42127 | 0.120 |
Why?
|
| Extracorporeal Circulation | 2 | 2023 | 34 | 0.110 |
Why?
|
| Perfusion | 2 | 2023 | 234 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 158 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 125 | 0.090 |
Why?
|
| Risk Factors | 4 | 2023 | 5447 | 0.090 |
Why?
|
| Graft Survival | 2 | 2024 | 895 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6757 | 0.080 |
Why?
|
| Adolescent | 1 | 2021 | 9201 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2647 | 0.080 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 352 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 1989 | 0.070 |
Why?
|
| Heart-Assist Devices | 1 | 2011 | 752 | 0.060 |
Why?
|
| HIV | 1 | 2024 | 48 | 0.060 |
Why?
|
| Blood Group Incompatibility | 1 | 2023 | 20 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2023 | 85 | 0.050 |
Why?
|
| Morbidity | 1 | 2023 | 149 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2023 | 72 | 0.050 |
Why?
|
| Alemtuzumab | 1 | 2022 | 85 | 0.050 |
Why?
|
| Death | 1 | 2023 | 85 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2023 | 166 | 0.050 |
Why?
|
| Heart Failure | 1 | 2011 | 1172 | 0.050 |
Why?
|
| Telomere Shortening | 1 | 2021 | 25 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2022 | 2273 | 0.050 |
Why?
|
| Brain Death | 1 | 2023 | 82 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 119 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 254 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 991 | 0.050 |
Why?
|
| Reoperation | 1 | 2024 | 598 | 0.050 |
Why?
|
| Shock, Cardiogenic | 1 | 2022 | 105 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2022 | 202 | 0.050 |
Why?
|
| Ablation Techniques | 1 | 2021 | 36 | 0.050 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2021 | 27 | 0.050 |
Why?
|
| Telomere | 1 | 2021 | 113 | 0.050 |
Why?
|
| Bronchi | 1 | 2022 | 229 | 0.050 |
Why?
|
| Ischemia | 1 | 2022 | 250 | 0.050 |
Why?
|
| Coronary Artery Bypass | 1 | 2022 | 233 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2022 | 159 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 485 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 386 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 847 | 0.040 |
Why?
|
| Heart | 1 | 2022 | 573 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2019 | 94 | 0.040 |
Why?
|
| Esophagus | 1 | 2019 | 106 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2020 | 168 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2024 | 1061 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2022 | 975 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 778 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 967 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 1399 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1862 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 478 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 936 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2011 | 94 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 301 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1591 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3649 | 0.010 |
Why?
|